165 related articles for article (PubMed ID: 36849939)
21. Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy.
Im E; Sim DY; Lee HJ; Park JE; Park WY; Ko S; Kim B; Shim BS; Kim SH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):1066-1075. PubMed ID: 34428551
[TBL] [Abstract][Full Text] [Related]
22. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
23. microRNA-146a Promotes Growth of Acute Leukemia Cells by Downregulating Ciliary Neurotrophic Factor Receptor and Activating JAK2/STAT3 Signaling.
Wang L; Zhang H; Lei D
Yonsei Med J; 2019 Oct; 60(10):924-934. PubMed ID: 31538427
[TBL] [Abstract][Full Text] [Related]
24. Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA).
Wang T; Wang K; Zhang Y; Zhang K; Cai S; Jiang S; Xiao Y; Zhang X
J Med Chem; 2023 Sep; 66(17):11881-11892. PubMed ID: 37594853
[TBL] [Abstract][Full Text] [Related]
25. Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.
Zhou J; Chong PS; Lu X; Cheong LL; Bi C; Liu SC; Zhou Y; Tan TZ; Yang H; Chung TH; Zeng Q; Chng WJ
Exp Hematol; 2014 Dec; 42(12):1041-52.e1-2. PubMed ID: 25139404
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
Zhao W; Zhang T; Qu B; Wu X; Zhu X; Meng F; Gu Y; Shu Y; Shen Y; Sun Y; Xu Q
Anticancer Drugs; 2011 Jan; 22(1):79-88. PubMed ID: 20881478
[TBL] [Abstract][Full Text] [Related]
27. [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients].
Ge MJ; Xu KL; Xu T; Tang YN; Li ZY; Yan ZL; Sun HY; Cheng H; Zhu F; Sang W; Huang YH; Qiu TT; Li DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):748-752. PubMed ID: 32552931
[TBL] [Abstract][Full Text] [Related]
28. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
[TBL] [Abstract][Full Text] [Related]
29. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6.
Schuringa JJ; Wierenga AT; Kruijer W; Vellenga E
Blood; 2000 Jun; 95(12):3765-70. PubMed ID: 10845908
[TBL] [Abstract][Full Text] [Related]
30. Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis.
Li F; Ye W; Yao Y; Wei W; Lin X; Zhuang H; Li C; Li X; Ling Q; Hu C; Huang X; Qian Y; Mao S; Huang J; Lu Y; Jin J
J Transl Med; 2023 Feb; 21(1):115. PubMed ID: 36774517
[TBL] [Abstract][Full Text] [Related]
31. STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.
Bruserud Ø; Nepstad I; Hauge M; Hatfield KJ; Reikvam H
Expert Rev Hematol; 2015 Feb; 8(1):29-41. PubMed ID: 25374305
[TBL] [Abstract][Full Text] [Related]
32.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
33. Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity.
Yasinska IM; Meyer NH; Schlichtner S; Hussain R; Siligardi G; Casely-Hayford M; Fiedler W; Wellbrock J; Desmet C; Calzolai L; Varani L; Berger SM; Raap U; Gibbs BF; Fasler-Kan E; Sumbayev VV
Front Immunol; 2020; 11():580557. PubMed ID: 33329552
[TBL] [Abstract][Full Text] [Related]
34. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
35. [Effect of MiR-29b-3p Targeting STAT3 on Proliferation and Apoptosis of Acute Myeloid Leukemia Cells].
Lin LP; Zhang Q; Wu W; Xue Y; Tang YJ; Lin DH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1853-1858. PubMed ID: 33283710
[TBL] [Abstract][Full Text] [Related]
36. [Expression and Clinical Significance of STAT3 Genes in Patients with Acute Myeloid Leukemia].
Huang CS; Tan M; Zhang XM; Luo X; Tian RM; Su Q; Wu LS; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):45-51. PubMed ID: 30738446
[TBL] [Abstract][Full Text] [Related]
37. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
Kortylewski M; Moreira D
Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
[TBL] [Abstract][Full Text] [Related]
38. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
Yoshida A; Ookura M; Zokumasu K; Ueda T
Biochem Pharmacol; 2014 Jul; 90(1):16-24. PubMed ID: 24735609
[TBL] [Abstract][Full Text] [Related]
39. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
[TBL] [Abstract][Full Text] [Related]
40. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
